East Windsor, NJ (November 4, 2014) – Another significant study on the combination of Curcumin C3 Complex® and BioPerine®, Lipid-­‐modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial, by researchers at University of Medical Sciences, Mashhad, Iran, has been published in Complementary Therapies in Medicine 2014; 22(5): 851-­‐857.

 

A randomized, double-­‐blind, placebo-­‐controlled, parallel group clinical trial was conducted with 117 patients for 8 weeks. Patients received either Curcumin C3 Complex® plus BioPerine® combination or matched placebo capsules twice daily for 8 weeks. Complete lipid profile including LDL-­‐C, non-­‐HDL-­‐C, Total Cholesterol, Triglyceride and Lp(a) were determined at the baseline and at end of the trial.

 

The study results showed significantly greater effect of Curcuminoids in reducing the serum concentrations of LDL-­‐C, non-­‐HDL-­‐C, total cholesterol, triglycerides and Lp(a) in comparison to the placebo group. Serum HDL-­‐C concentration was elevated significantly in the Curcuminoids group. Serum sdLDL levels were comparable in both groups at baseline and at the end of the trial. Overall effects of Curcuminoids on triglycerides, non-­‐HDL-­‐C, total cholesterol and Lp(a) remained significant after adjustment for baseline BMI. Curcumin C3 Complex® plus BioPerine® combination was well tolerated in patients with metabolic syndrome.

 

This study is the first trial investigating the efficacy and safety of adjunctive therapy with Curcuminoids-­Piperine combination in patients with metabolic syndrome, receiving standard treatment. The results of the trial supported the effectiveness of the adjunctive therapy with significant decrease in serum concentration LDL-­‐C, non-­‐HDL-­‐C, total cholesterol, triglyceride, Lp(a) and elevation in serum concentration of HDL-­‐C in patients in comparison to the standard therapy alone. The present study also encouraged the efficacy of use of co-­‐administering BioPerine® as a bioavailability enhancer.

 

“This research indicates additional benefits of Curcumin beyond inflammation, giving increased value to C3 Complex as the body of science grows” said Shaheen Majeed, Sabinsa Marketing Director. “And once again the C3 Complex and BioPerine combination has been shown to be a safe and effective supplement blend that can help keep people healthy.”

 

Sabinsa’s Curcumin C3 Complex® has been subject of over 72 research papers including 34 clinical studies published in peer reviewed journals. The combination of Curcumin C3 Complex® and BioPerine® has been studied in several independent clinical trials, including one published by Tufts University validating its safety and quality of ingredients and another on osteoarthritis from University of Medical Sciences, Mashhad, Iran.

About Sabinsa Corporation: Sabinsa’s mission is to provide alternative and complementary natural products for human nutrition and well being. Over the past 26 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-­‐time scientists conducting ongoing research in India and the United States, Sabinsa and sister company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market. All products intended for human consumption are certified Kosher and Halal. For more information, visit www.sabinsa.com.